Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hormone replacement therapy public meeting

Executive Summary

National Institutes of Health will host a public meeting to discuss results of the Women's Health Initiative trial Oct. 23-24 at 8:30 a.m. in the Natcher Conference Center. The trial was halted in July after a finding of an increased risk of breast cancer and adverse cardiovascular outcomes among subjects on Wyeth's Prempro (progestin/medroxyprogesterone) (1"The Pink Sheet" July 15, p. 11). FDA plans to host a public session in the fall to discuss whether the WHI results can be extrapolated to other combination estrogen/progestin products (2"The Pink Sheet" Aug. 19, p.11). The U.S. Preventive Services Task Force, sponsored by the Agency for Healthcare Research & Quality, plans to make public new recommendations on hormone replacement therapy use in the fall, NIH said...

You may also be interested in...

Premarin/Prempro Rxs Stabilize; Wyeth Predicts $300 Mil. Drop In 2nd Half

Wyeth is seeing some stabilization in the Premarin franchise despite a 40% drop in prescriptions for Prempro and a 15% decline in Premarin scripts since release of the Women's Health Initiative study results

Wyeth Prempro Updated Label Submission Soon; HHS To Discuss WHI Results

Wyeth expects to submit updated Prempro labeling reflecting the results of the Women's Health Initiative study on use of the hormone replacement therapy soon, the company said

Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review

Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts